The global demand for Bacteriophage Therapy Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Bacteriophage therapy or phage therapy utilizes bacteriophages to treat bacterial infections. Bacteriophage or phage is the type of virus that gets attached to the bacterial cell and injects viral genome or DNA into the bacterial cell. The viral genome takes the place of the bacterial genome and eventually stops further bacterial growth and infection. The bacterial cell with viral genome replicates bacteriophages. Bacteriophages are compared with antibiotics as both effectively kill infection-causing bacteria; however, bacteriophages are more specific in action than antibiotics. They do not harm host cells as well as to other beneficial bacteria such as gut flora in the host body. Bacteriophages are an alternative therapy to antibiotics as many infectious bacteria are now resistant to the regularly used broad-spectrum antibiotics.
Market Dynamics
The factors that are driving the global bacteriophage market are the increasing prevalence of air, water, and foodborne bacterial infection, and increasing incidences of antibiotic resistance. Besides, there are almost nil or few side effects of bacteriophage therapy. This factor is supporting the global market. Moreover, extensive R & D on bacteriophage therapy by private as well as government sectors is further fuelling the global market. During the COVID-19 pandemic, the bacteriophage therapy market is likely to expand as the entire global focus is on the development of new treatment therapies for infections.
The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of bacteriophage therapy.
Market Segmentation
The entire bacteriophage therapy market has been sub-categorized into targeted bacteria and route of administration. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Targeted Bacteria
- Escherichia Coli
- Staphylococcus
- Streptococcus
- Pseudomonas
- Salmonella
- Others
By Route of Administration
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for bacteriophage therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Bacteriophage Therapy Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the bacteriophage therapy market include Armata Pharmaceuticals, Inc., Eliava Biopreparations Ltd., Pherecydes Pharma, Intralytix, Inc., Phagelux Inc., Nextbiotics, InnoPhage, Ltd, Locus Biosciences, Inc., TechnoPhage, Eligo Bioscience SA, Phagomed Biopharma GmbH., PhagePro, Inc., Adaptive Phage Therapeutics, Inc., EnBiotix, Inc., Intodeworld, Inc., BiomX Ltd., Phi Therapeutics, Fixed-phage Ltd., Micreos BV, and ContraFect Corporation. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.